503 related articles for article (PubMed ID: 18402297)
1. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
[TBL] [Abstract][Full Text] [Related]
2. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
Li L; Tian YJ; Shen H; Zhao XP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
[TBL] [Abstract][Full Text] [Related]
3. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
5. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
6. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
[TBL] [Abstract][Full Text] [Related]
7. A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.
Zhang Y; Su WJ; Wang J; Bai XF; Huang CX; Lian JQ
Viral Immunol; 2014 Nov; 27(9):430-7. PubMed ID: 25211639
[TBL] [Abstract][Full Text] [Related]
8. Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES.
Kim SJ; Suh D; Park SE; Park JS; Byun HM; Lee C; Lee SY; Kim I; Oh YK
Virology; 2003 Sep; 314(1):84-91. PubMed ID: 14517062
[TBL] [Abstract][Full Text] [Related]
9. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
10. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection.
Du DW; Jia ZS; Li GY; Zhou YY
World J Gastroenterol; 2003 Jan; 9(1):108-11. PubMed ID: 12508362
[TBL] [Abstract][Full Text] [Related]
11. Comparing the immunogenicity of hepatitis B virus S gene variants by DNA immunization.
Wu L; Yuan ZH; Liu F; Waters JA; Wen YM
Viral Immunol; 2001; 14(4):359-67. PubMed ID: 11792065
[TBL] [Abstract][Full Text] [Related]
12. Enhancing cellular immune response to HBV M DNA vaccine in mice by codelivery of interleukin-18 recombinant.
Chen JZ; Zhu HH; Liu KZ; Chen Z
J Zhejiang Univ Sci; 2004 Apr; 5(4):467-71. PubMed ID: 14994439
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with a DNA vaccine encoding CD317-targeting HBs antigen elicits enhanced immunity in mice.
Zhang G; Li X; Liu L; Li J; Chen Q; Huang S; Li Y; Wan X
Biochem Biophys Res Commun; 2018 Oct; 504(4):865-870. PubMed ID: 30219230
[TBL] [Abstract][Full Text] [Related]
14. A novel hepatitis B virus variant S 129 (Gln-->Leu): lack of correlation between antigenicity and immunogenicity.
Wu L; He JW; Yao X; Li HM; Wen YM
J Med Virol; 1999 Dec; 59(4):424-30. PubMed ID: 10534722
[TBL] [Abstract][Full Text] [Related]
15. [Reciprocal priming-boosting role of HBsAg and DNA vaccines].
Zhou Z; Chen WS; Zhang HH; Yao JL
Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):212-4. PubMed ID: 12716517
[TBL] [Abstract][Full Text] [Related]
16. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.
Zhu W; Wu C; Deng W; Pei R; Wang Y; Cao L; Qin B; Lu M; Chen X
PLoS One; 2012; 7(9):e45146. PubMed ID: 23024803
[TBL] [Abstract][Full Text] [Related]
18. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice.
Qing Y; Chen M; Zhao J; Hu H; Xu H; Ling N; Peng M; Ren H
Vaccine; 2010 Jun; 28(26):4301-7. PubMed ID: 20430121
[TBL] [Abstract][Full Text] [Related]
19. Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen.
Shen M; Wang S; Ge G; Xing Y; Ma X; Huang Z; Lu S
Vaccine; 2010 Oct; 28(45):7288-96. PubMed ID: 20831917
[TBL] [Abstract][Full Text] [Related]
20. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
